1. Cell Biology

Adiponectin receptor agonist AdipoRon improves skeletal muscle function in aged mice

  1. Priya Balasubramanian
  2. Anne E Schaar
  3. Grace E Gustafson
  4. Alex B Smith
  5. Porsha R Howell
  6. Angela Greenman
  7. Scott Baum
  8. Ricki J Colman
  9. Dudley W Lamming
  10. Gary M Diffee
  11. Rozalyn M Anderson  Is a corresponding author
  1. University of Wisconsin-Madison, United States
https://doi.org/10.7554/eLife.71282
Share this article
Cite this article
  1. Priya Balasubramanian
  2. Anne E Schaar
  3. Grace E Gustafson
  4. Alex B Smith
  5. Porsha R Howell
  6. Angela Greenman
  7. Scott Baum
  8. Ricki J Colman
  9. Dudley W Lamming
  10. Gary M Diffee
  11. Rozalyn M Anderson
(2022)
Adiponectin receptor agonist AdipoRon improves skeletal muscle function in aged mice
eLife 11:e71282.
https://doi.org/10.7554/eLife.71282
  2. Download BibTeX
  3. Download .RIS

Abstract

The loss of skeletal muscle function with age, known as sarcopenia, significantly reduces independence and quality of life and can have significant metabolic consequences. Although exercise is effective in treating sarcopenia it is not always a viable option clinically, and currently there are no pharmacological therapeutic interventions for sarcopenia. Here we show that chronic treatment with pan-adiponectin receptor agonist AdipoRon improved muscle function in male mice by a mechanism linked to skeletal muscle metabolism and tissue remodeling. In aged mice, 6 weeks of AdipoRon treatment improved skeletal muscle functional measures in vivo and ex vivo. Improvements were linked to changes in fiber type, including an enrichment of oxidative fibers, and an increase in mitochondrial activity. In young mice, 6 weeks of AdipoRon treatment improved contractile force and activated the energy sensing kinase AMPK and the mitochondrial regulator PGC-1a (peroxisome proliferator activated receptor gamma coactivator 1 alpha). In cultured cells, the AdipoRon induced stimulation of AMPK and PGC-1a was associated with increased mitochondrial membrane potential, reorganization of mitochondrial architecture, increased respiration, and increased ATP production. Furthermore, the ability of AdipoRon to stimulate AMPK and PGC1a was conserved in nonhuman primate cultured cells. These data show that AdipoRon is an effective agent for the prevention of sarcopenia in mice and indicate that its effects translate to primates, suggesting it may also be a suitable therapeutic for sarcopenia in clinical application.

Data availability

All data generated or analyzed during this experimental study are included in the manuscript and supporting files used to generate figures 1-6 have been deposited to Dryad at URL (https://doi.org/10.5061/dryad.x95x69pkt)

The following data sets were generated

Article and author information

Author details

  1. Priya Balasubramanian

    Department of Medicine, University of Wisconsin-Madison, Madison, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0912-5363

  2. Anne E Schaar

    Department of Medicine, University of Wisconsin-Madison, Madison, United States
    Competing interests
    The authors declare that no competing interests exist.

  3. Grace E Gustafson

    Department of Medicine, University of Wisconsin-Madison, Madison, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8343-4493

  4. Alex B Smith

    Department of Medicine, University of Wisconsin-Madison, Madison, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2615-8899

  5. Porsha R Howell

    Department of Medicine, University of Wisconsin-Madison, Madison, United States
    Competing interests
    The authors declare that no competing interests exist.

  6. Angela Greenman

    Department of Kinesiology, University of Wisconsin-Madison, Madison, United States
    Competing interests
    The authors declare that no competing interests exist.

  7. Scott Baum

    Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, United States
    Competing interests
    The authors declare that no competing interests exist.

  8. Ricki J Colman

    Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, United States
    Competing interests
    The authors declare that no competing interests exist.

  9. Dudley W Lamming

    Department of Medicine, University of Wisconsin-Madison, Madison, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0079-4467

  10. Gary M Diffee

    Department of Kinesiology, University of Wisconsin-Madison, Madison, United States
    Competing interests
    The authors declare that no competing interests exist.

  11. Rozalyn M Anderson

    Department of Medicine, University of Wisconsin-Madison, Madison, United States
    For correspondence
    rozalyn.anderson@wisc.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0864-7998

Funding

U.S. Department of Veterans Affairs (BX003846)

  • Priya Balasubramanian
  • Anne E Schaar
  • Rozalyn M Anderson

U.S. Department of Veterans Affairs (BX004031)

  • Dudley W Lamming

National Institute on Aging (AG040178)

  • Alex B Smith
  • Scott Baum
  • Ricki J Colman
  • Rozalyn M Anderson

National Institute on Aging (AG056771)

  • Dudley W Lamming

National Institutes of Health (AG000213)

  • Anne E Schaar

National Institutes of Health (GM083252)

  • Porsha R Howell

National Institutes of Health (P51OD011106)

  • Scott Baum
  • Ricki J Colman

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health to minimize animal harm and suffering. All animal protocols were approved by the Institutional Animal Care and Use Committee at the University of Wisconsin, Madison on animal protocols #RA-0005-1 and #RA-0007-1

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 2,159
    views
  • 393
    downloads
  • 29
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Priya Balasubramanian
  2. Anne E Schaar
  3. Grace E Gustafson
  4. Alex B Smith
  5. Porsha R Howell
  6. Angela Greenman
  7. Scott Baum
  8. Ricki J Colman
  9. Dudley W Lamming
  10. Gary M Diffee
  11. Rozalyn M Anderson
(2022)
Adiponectin receptor agonist AdipoRon improves skeletal muscle function in aged mice
eLife 11:e71282.
https://doi.org/10.7554/eLife.71282

Share this article

https://doi.org/10.7554/eLife.71282

Categories and tags

Research organisms

Further reading

    1. Cell Biology

    Oversized cells activate global proteasome-mediated protein degradation to maintain cell size homeostasis

    Shixuan Liu, Ceryl Tan ... Ran Kafri
    Research Advance Updated

    Proliferating animal cells maintain a stable size distribution over generations despite fluctuations in cell growth and division size. Previously, we showed that cell size control involves both cell size checkpoints, which delay cell cycle progression in small cells, and size-dependent regulation of mass accumulation rates (Ginzberg et al., 2018). While we previously identified the p38 MAPK pathway as a key regulator of the mammalian cell size checkpoint (Liu et al., 2018), the mechanism of size-dependent growth rate regulation has remained elusive. Here, we quantified global rates of protein synthesis and degradation in cells of varying sizes, both under unperturbed conditions and in response to perturbations that trigger size-dependent compensatory growth slowdown. We found that protein synthesis rates scale proportionally with cell size across cell cycle stages and experimental conditions. In contrast, oversized cells that undergo compensatory growth slowdown exhibit a superlinear increase in proteasome-mediated protein degradation, with accelerated protein turnover per unit mass, suggesting activation of the proteasomal degradation pathway. Both nascent and long-lived proteins contribute to the elevated protein degradation during compensatory growth slowdown, with long-lived proteins playing a crucial role at the G1/S transition. Notably, large G1/S cells exhibit particularly high efficiency in protein degradation, surpassing that of similarly sized or larger cells in S and G2, coinciding with the timing of the most stringent size control in animal cells. These results collectively suggest that oversized cells reduce their growth efficiency by activating global proteasome-mediated protein degradation to promote cell size homeostasis.

    1. Cell Biology

    Artesunate, EDTA, and colistin work synergistically against MCR-negative and -positive colistin-resistant Salmonella

    Yajun Zhai, Peiyi Liu ... Gongzheng Hu
    Research Article

    Discovering new strategies to combat the multidrug-resistant bacteria constitutes a major medical challenge of our time. Previously, artesunate (AS) has been reported to exert antibacterial enhancement activity in combination with β-lactam antibiotics via inhibition of the efflux pump AcrB. However, combination of AS and colistin (COL) revealed a weak synergistic effect against a limited number of strains, and few studies have further explored its possible mechanism of synergistic action. In this article, we found that AS and EDTA could strikingly enhance the antibacterial effects of COL against mcr-1- and mcr-1+ Salmonella strains either in vitro or in vivo, when used in triple combination. The excellent bacteriostatic effect was primarily related to the increased cell membrane damage, accumulation of toxic compounds and inhibition of MCR-1. The potential binding sites of AS to MCR-1 (THR283, SER284, and TYR287) were critical for its inhibition of MCR-1 activity. Additionally, we also demonstrated that the CheA of chemosensory system and virulence-related protein SpvD were critical for the bacteriostatic synergistic effects of the triple combination. Selectively targeting CheA, SpvD, or MCR using the natural compound AS could be further investigated as an attractive strategy for the treatment of Salmonella infection. Collectively, our work opens new avenues toward the potentiation of COL and reveals an alternative drug combination strategy to overcome COL-resistant bacterial infections.

    1. Cell Biology

    A ‘torn bag mechanism’ of small extracellular vesicle release via limiting membrane rupture of en bloc released amphisomes (amphiectosomes)

    Tamás Visnovitz, Dorina Lenzinger ... Edit I Buzas
    Short Report

    Recent studies showed an unexpected complexity of extracellular vesicle (EV) biogenesis pathways. We previously found evidence that human colorectal cancer cells in vivo release large multivesicular body-like structures en bloc. Here, we tested whether this large EV type is unique to colorectal cancer cells. We found that all cell types we studied (including different cell lines and cells in their original tissue environment) released multivesicular large EVs (MV-lEVs). We also demonstrated that upon spontaneous rupture of the limiting membrane of the MV-lEVs, their intraluminal vesicles (ILVs) escaped to the extracellular environment by a ‘torn bag mechanism’. We proved that the MV-lEVs were released by ectocytosis of amphisomes (hence, we termed them amphiectosomes). Both ILVs of amphiectosomes and small EVs separated from conditioned media were either exclusively CD63 or LC3B positive. According to our model, upon fusion of multivesicular bodies with autophagosomes, fragments of the autophagosomal inner membrane curl up to form LC3B positive ILVs of amphisomes, while CD63 positive small EVs are of multivesicular body origin. Our data suggest a novel common release mechanism for small EVs, distinct from the exocytosis of multivesicular bodies or amphisomes, as well as the small ectosome release pathway.